Treatment for Hepatitis C through Washington Apple Health Elisabeth S. Smith Northwest Health Law Advocates June 3, 2016.

Slides:



Advertisements
Similar presentations
African Americans and Hepatitis C
Advertisements

Wisconsin D.O.C. Approach to Hepatitis C Treatment Edward Wall Secretary Jim Greer Bureau Director Health Services Wisconsin Department of Corrections.
1 Rick Scott, Governor Barbara Palmer, Director Geraud Moreland II, et al v. Palmer, Case No. 4:12-cv MW-CAS (N.D. Fla.)
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-I.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1 ION-3 Phase 3 Treatment Naïve Kowdley K, et al. N Engl J Med.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIAID SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I Phase 3 Treatment Naïve Feld JJ, et.
Software Patents for Higher Education ICPL August 12, 2008.
By: Taylor Lawrence.  Cirrhosis is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions. This occurs.
 Professional society founded in 1954 representing 3,100+ physicians & other associated professionals  Mission:  Increase access to & improve the quality.
National policy on Hepatitis B at the Workplace
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
Randy Costales Executive Director, The Arc of New Mexico 1.
1 Medicaid Citizenship Documentation Requirement Presented by Elaine M. Ryan October 13, 2006.
Evaluation of Liver Histology in Clinical Trials for Chronic Viral Hepatitis Zachary Goodman, M.D., Ph.D. Chief, Hepatic Pathology Armed Forces Institute.
Patient Information - Viral Hepatitis B (HBV)
Study Finds Persons Who Fill Buprenorphine Prescriptions Have Higher Rates of Medical Conditions Associated with Pain and Comorbid Psychiatric Disorders.
ADAP and Hepatitis B Coverage  In June 2012, 29 ADAPs covered at least one of the medications for HBV on their formularies.  ADAPs filled 325 hepatitis.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
Dependency Briefs What you need to know when a dependent child is in out of home care for 15 of the last 22 months – in 12 slides!
Welcome to the Safe Table. Carol Wagner, Senior Vice President Patient Safety Washington State Hospital Association Susan Callahan, Director of Community.
Ms. Fredericka Roper. What is P4HB? AKA “Medicaid Waiver Program for Women” A state Medicaid waiver program that offers FP services for women who do not.
Washington Apple Health Washington Coalition of Medicaid Outreach Amy Johnson, Eligibility Policy and Service Delivery June 19, 2015.
Reducing Preventable Emergency Room Visits 1. An Opportunity Redirecting care to the most appropriate setting protects patient safety and ensures payment.
1 Prescribing Pain Medication – Guidelines for the Emergency Department April 22, 2012 Jennifer Sabel, PhD.
Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment Experienced.
Hepatitis C: Where are we? Where do we want to go?
Hepatitis C in Egypt Seif Tamer Ahmed Naser. What is it? Liver disease caused by Hepatitis C virus Can range from mild illness lasting a few weeks to.
CASE 2 58 yo man IVDU in past….last used 35 yrs ago Genotype 1a Chronic Hepatitis C Type II Diabetes Private drug plan coverage.
REVIEW PROCESS FOR CDC+. Important Numbers Phone & fax numbers for consultants to contact eQHealth Voice: Fax:
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in HCV Genotype 4 NIAID SYNERGY (Genotype 4) Phase 2 Treatment Naïve and Treatment Experienced.
The ACA and Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) Implications for Tobacco Cessation Therapies Steve Melek, FSA, MAAA February.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir +/- 3 rd DAA in HCV Genotype 1 NIH SYNERGY Phase 2 Treatment Naïve (unfavorable baseline.
Sheldon Toubman, Staff Attorney New Haven Legal Assistance Association (203) , ext June 17, 2016 STRATEGIES FOR CONVINCING.
Sharla Smith.  Feedback  Questions  Government Health Insurance  Medicare  Medicaid  CHIP.
INSERVICE AN INTERACTIVE JOURNEY BY NICK AND JONO.
HCV Update: 18 July 2016 Ardis Ann Moe, M.D.
HILLS SPINALS H T T P : / / W W W. H I L L S S P I N A L. C O M / + SPINAL HEALTH CHIROPRACTIC CARE.
Where Are We on the Path to Elimination of Chronic Hepatitis C?
A Providers Perspective: Management and Treatment of HCV in PWID
Applied Kinesiology Chiropractic Computerised Gait Analysis Detox Programs Exercise & Rehab Programs Massage NeuroEmotional Technique (NET) Neurological.
Phase 3 Treatment-Naïve and Treatment-Experienced
Definition of School Nursing
BACKGROUND MATERIALS & METHODS RESULTS CONCLUSIONS
Accessing Meds, State of Medicaid and Patient Management Tools
Talking to Patients About HCV Treatment
Establishing a Pharmacy Managed HCV Service
“Sick around the world” 1
for Community Partners
Treating Hep C with Novel Agents
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
Phase 2 Treatment Naïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype.
Generics – what can be done
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Update on Integration: HCA’s Vision
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
(A) Meta-analysis retention: Forest plot of the proportion of HIV-infected adolescents and young adults in South Africa retained in care. (A) Meta-analysis.
Hepatitis C in the HIV-infected patient
Phase 3 Treatment-Naïve and Treatment-Experienced
Presented by: Jeanette Shabazz, PhD, NP-C
Medicaid Waivers Litigation Update
Hepatitis C Virus Diagnosis and the Holy Grail
Systematic review: Perinatally HIV-infected infants in South Africa, total HIV-infected children aged 0–14 and the approaching wave of HIV-infected adolescents.
© The Author(s) Published by Science and Education Publishing.
Markov model of HCV–HCC disease process.
post intervention (n=60)
Managing Hepatitis C in Vermont
Treatment success rate (cured and treatment completed) of patients with new tuberculosis (TB) treated in intervention zone by gender and age. Treatment.
Amy Kapczynski YLS Panel on Drug Pricing Sept. 26, 2016
Presentation transcript:

Treatment for Hepatitis C through Washington Apple Health Elisabeth S. Smith Northwest Health Law Advocates June 3, 2016

Hepatitis C 1.Liver health for those who are infected with Hepatitis C is graded according to the level of liver scarring under a fibrosis score. The scoring ranges from a score of F0 (mild scarring or scarring absent) to F4 (significant liver damage; cirrhosis). 2.Harvoni® is a prescription drug that effectively cures Hep C in more than 90% of the individuals who are treated with it. 3.However, until recently the Health Care Authority would only approve Medicaid coverage of Harvoni for individuals with a fibrosis score of 3 or 4.

Preliminary Injunction Last week U.S. District Court Judge John C. Coughenour granted a preliminary injunction ordering HCA to begin covering Harvoni “without regard to fibrosis score.” Lawsuit (B.E. et al v. Teeter) will continue, but HCA has not publicly commented on the injunction.

Contact If you hear of a Medicaid client being denied Harvoni, please contact: Amy Crewdson Columbia Legal Services 711 Capitol Way South #304 Olympia WA (360) x x. 214 (360) (360) (fax)